LLY

765.39

+2.52%↑

JNJ

176.33

-0.45%↓

ABBV

216.67

+0.17%↑

UNH

341.11

-2.21%↓

AZN

77.87

-0.12%↓

LLY

765.39

+2.52%↑

JNJ

176.33

-0.45%↓

ABBV

216.67

+0.17%↑

UNH

341.11

-2.21%↓

AZN

77.87

-0.12%↓

LLY

765.39

+2.52%↑

JNJ

176.33

-0.45%↓

ABBV

216.67

+0.17%↑

UNH

341.11

-2.21%↓

AZN

77.87

-0.12%↓

LLY

765.39

+2.52%↑

JNJ

176.33

-0.45%↓

ABBV

216.67

+0.17%↑

UNH

341.11

-2.21%↓

AZN

77.87

-0.12%↓

LLY

765.39

+2.52%↑

JNJ

176.33

-0.45%↓

ABBV

216.67

+0.17%↑

UNH

341.11

-2.21%↓

AZN

77.87

-0.12%↓

Search

Xenon Pharmaceuticals Inc

Open

SectorGezondheidszorg

35.97 0.22

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

35.42

Max

36.24

Belangrijke statistieken

By Trading Economics

Inkomsten

-20M

-85M

Winstmarge

-867.293

Werknemers

316

EBITDA

-21M

-94M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+48.18% upside

Dividenden

By Dow Jones

Volgende Winsten

11 nov 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

327M

2.9B

Vorige openingsprijs

35.75

Vorige sluitingsprijs

35.97

Nieuwssentiment

By Acuity

50%

50%

183 / 371 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Strong Bearish Evidence

Xenon Pharmaceuticals Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

15 sep 2025, 22:39 UTC

Acquisities, Fusies, Overnames

CSL Agrees to Deal to Advance Coagulation Treatment, May Acquire Developer

15 sep 2025, 16:43 UTC

Belangrijke Marktbewegers

Strive Shares Sink on Board Disclosure; Bitcoin Treasury Strategy

15 sep 2025, 16:42 UTC

Belangrijke Marktbewegers

Helius Medical Tech Jumps on Funding to Launch Solana Treasury

15 sep 2025, 16:35 UTC

Belangrijke Marktbewegers

Chegg to Pay $7.5 Million to Settle FTC Claims Over Subscription Cancellation Process

15 sep 2025, 23:46 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

15 sep 2025, 23:46 UTC

Marktinformatie

Nikkei May Rise as Fed Rate Cut Hopes Support Stocks -- Market Talk

15 sep 2025, 23:34 UTC

Marktinformatie

Gold Steady Ahead of FOMC Meeting, Major U.S. Economic Data -- Market Talk

15 sep 2025, 22:48 UTC

Marktinformatie

FOMC May Opt to Play Catch Up With Rate Cuts -- Market Talk

15 sep 2025, 22:12 UTC

Acquisities, Fusies, Overnames

CSL Expects Commercial Launch in 2029

15 sep 2025, 22:12 UTC

Acquisities, Fusies, Overnames

CSL Says VarmX to Receive Further Commercial Milestones Afterwards

15 sep 2025, 22:11 UTC

Acquisities, Fusies, Overnames

CSL Says VarmX to Receive Payments of Up to $388 Million Up to Launch of VMX-C001

15 sep 2025, 22:11 UTC

Acquisities, Fusies, Overnames

CSL to Have Right to Exercise Option Based on Phase 3 Data

15 sep 2025, 22:10 UTC

Acquisities, Fusies, Overnames

CSL to Make Upfront Payment to VarmX of $117 Million for Exclusive Option to Acquire Company

15 sep 2025, 21:16 UTC

Acquisities, Fusies, Overnames

Chord Energy: Assets Have a Low Avg NYMEX WTI Breakeven and Are Immediately Competitive for Capital

15 sep 2025, 21:16 UTC

Acquisities, Fusies, Overnames

Chord Energy: Assets Have Significant Overlap With Existing Footprint, Setting the Stage for Long-Lateral Development

15 sep 2025, 21:15 UTC

Acquisities, Fusies, Overnames

Chord Energy to Buy 48,000 Net Acres in the Williston Core

15 sep 2025, 21:14 UTC

Acquisities, Fusies, Overnames

Chord Energy to Buy Assets in Williston Basin From Exxon's XTO Energy and Affiliates for $550M

15 sep 2025, 20:50 UTC

Marktinformatie

Auto & Transport Roundup: Market Talk

15 sep 2025, 20:50 UTC

Marktinformatie

Financial Services Roundup: Market Talk

15 sep 2025, 20:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

15 sep 2025, 19:29 UTC

Marktinformatie

U.S. Natural Gas Gains on Warmer Weather Outlook -- Market Talk

15 sep 2025, 19:14 UTC

Marktinformatie

Attacks on Russia Lifts Oil Price Despite Shaky Fundamentals -- Market Talk

15 sep 2025, 18:16 UTC

Marktinformatie

Gold Powers to New High -- Market Talk

15 sep 2025, 18:05 UTC

Marktinformatie

Easing Autonomous Vehicle Regulations Will Begin Tesla's Next Chapter -- Market Talk

15 sep 2025, 17:50 UTC

Acquisities, Fusies, Overnames

U.S. Reaches Outline of Deal With China Over TikTok -- 2nd Update

15 sep 2025, 17:10 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

15 sep 2025, 17:10 UTC

Marktinformatie

S&P Expects Fed, BOC to Cut Rates -- Market Talk

15 sep 2025, 16:52 UTC

Marktinformatie

Copper Climbs as Traders Brace for U.S. Rate Cut -- Market Talk

15 sep 2025, 16:20 UTC

Marktinformatie

Financial Services Roundup: Market Talk

15 sep 2025, 16:20 UTC

Marktinformatie
Winsten

Auto & Transport Roundup: Market Talk

Peer Vergelijking

Prijswijziging

Xenon Pharmaceuticals Inc Prognose

Koersdoel

By TipRanks

48.18% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 53.33 USD  48.18%

Hoogste 60 USD

Laagste 48 USD

Gebaseerd op 11 Wall Street-analisten die 12-maands prijsdoelen bieden voor Xenon Pharmaceuticals Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

11 ratings

11

Buy

0

Hold

0

Sell

Technische score

By Trading Central

34.81 / 38.24Steun & Weerstand

Korte Termijn

Strong Bearish Evidence

Gemiddeld Termijn

Bullish Evidence

Lange Termijn

Neutral Evidence

Sentiment

By Acuity

183 / 371 Rangschikking in Gezondheidszorg

Nieuwssentiment

Neutral

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Xenon Pharmaceuticals Inc

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.
help-icon Live chat